Search hospitals > Missouri > Columbia
University of Missouri
Claim this profileColumbia, Missouri 65201
Global Leader in Obesity
Global Leader in Diabetes
Conducts research for Coronavirus
Conducts research for Motor Skills
Conducts research for Insomnia
301 reported clinical trials
30 medical researchers
Summary
University of Missouri is a medical facility located in Columbia, Missouri. This center is recognized for care of Obesity, Diabetes, Coronavirus, Motor Skills, Insomnia and other specialties. University of Missouri is involved with conducting 301 clinical trials across 575 conditions. There are 30 research doctors associated with this hospital, such as Puja Nistala, Christos Papageorgiou, Katie Murray, DO, MS, SACS, and Dima Dandachi, MD.Top PIs
Puja NistalaUniversity of Missouri - Ellis Fischel4 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
26 reported clinical trials
86 drugs studied
Christos PapageorgiouMU Health - University Hospital/Ellis Fischel Cancer Center2 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
10 reported clinical trials
26 drugs studied
Katie Murray, DO, MS, SACSUniversity of Missouri - Ellis Fischel4 years of reported clinical research
Studies Bladder Cancer
Studies Prostate Cancer
8 reported clinical trials
23 drugs studied
Dima Dandachi, MDGSK Investigational Site1 year of reported clinical research
Studies HIV Infection
Studies Human Immunodeficiency Virus Infection
6 reported clinical trials
9 drugs studied
Clinical Trials running at University of Missouri
Brain Tumor
Obesity
Age-Related Macular Degeneration
Insomnia
Asthma
Breast Cancer
Bacterial Infection
Dementia
Abdominal Aortic Aneurysm
Kidney Failure
RVP-001
for Brain Tumors
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis. The goal of this study is to assess safety, efficacy, and pharmacokinetics of RVP-001 at three dose levels. The study will also compare RVP-001 imaging to gadolinium-based contrast agent (GBCA) imaging. A single dose of RVP-001 will be administered to each subject. Subjects will have known gadolinium-enhancing CNS lesions and will have a gadolinium-based contrast agent-enhanced MRI of the brain 2-14 days before receiving RVP-001 with imaging. The ultimate goal of this research program is development of a gadolinium-free alternative to current general purpose MRI contrast agents.
Recruiting1 award Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Missouri?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.